Differentiating Between Progressive & Relapsing MS. ... a 2019 study in Multiple Sclerosis Journal found that fewer than 10% of patients with RRMS will develop SPMS over a median of three decades, ...

Up to 85% of the people who receive a diagnosis of the neurodegenerative disorder multiple sclerosis (MS) have the relapsing-remitting (RR) disease course. ... Secondary Progressive MS.

Heidi Crayton, MD, and Maria Lopes, MD, discuss the impact of multiple sclerosis on patients, families, and caregivers, differentiate relapsing forms (relapsing-remitting and primary progressive ...

Updates in safety, efficacy, and specificity may make switching treatments beneficial for people with secondary progressive multiple sclerosis (SPMS). Learn more.

Mitoxantrone hydrochloride was the first FDA-approved medication for both secondary-progressive multiple sclerosis (MS) and progressive-relapsing MS. It’s also used to treat relapsing-remitting ...

Basel, 16 September 2024- Roche announced that the United States Food and Drug Administration has approved OCREVUS ZUNOVO™ for the treatment of relapsing multiple sclerosis and primary ...

Further analyses by disease subtype showed that vidofludimus calcium was associated with a 33% reduction in 24wCDW in the primary progressive multiple sclerosis (PPMS) study population (n=152 ...

Tolebrutinib designated Breakthrough Therapy by the FDA for non-relapsing secondary progressive multiple sclerosis. Designation is based on positive results from the HERCULES study in adults with ...

The approval was based on data from the phase 3 ULTIMATE I (ClinicalTrials.gov Identifier: NCT03277261) and ULTIMATE II (ClinicalTrials.gov Identifier: NCT03277248) trials, which evaluated the ...

Ublituximab-xiiy, developed by TG Therapeutics, will be sold under the name Briumvi. The FDA recently approved ublituximab-xiiy for the treatment of relapsing forms of multiple sclerosis (RMS), to ...

FDA approves Ocrevus Zunovo™ as the first and only twice-a-year 10-minute subcutaneous injection for people with relapsing and progressive multiple sclerosis. News release. Genentech.